title: Visceral leishmaniasis treatment in the Indian subcontinent: how to reach the most vulnerable.
authors.forename: Albert
authors.initials: A
authors.lastname: Picado
authors.forename: Suman
authors.initials: S
authors.lastname: Rijal
authors.forename: Shyam
authors.initials: S
authors.lastname: Sundar
authors.forename: Marleen
authors.initials: M
authors.lastname: Boelaert
mesh_terms: D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000494:pharmacology; D003140:Communicable Disease Control / Q000331:legislation & jurisprudence / Q000379:methods; D006297:Health Services Accessibility / Q000331:legislation & jurisprudence*; D006801:Humans; D007194:India; D007303:Insect Vectors / Q000469:parasitology; D007893:Leishmania donovani / Q000472:pathogenicity*; D007898:Leishmaniasis, Visceral / Q000175:diagnosis / Q000188:drug therapy* / Q000469:parasitology / Q000517:prevention & control; D010767:Phosphorylcholine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D011576:Psychodidae / Q000469:parasitology
chemical_list: D000981:Antiprotozoal Agents; D010767:Phosphorylcholine; C039128:miltefosine